HAVN Life Sciences Inc.
HAVLF · OTC
4/30/2022 | 4/30/2021 | 4/30/2020 | |
|---|---|---|---|
| Market Cap | $8,252 | $77,447 | $66,262 |
| - Cash | $1,056 | $9,402 | $1,617 |
| + Debt | $389 | $456 | $0 |
| Enterprise Value | $7,586 | $68,501 | $64,645 |
| Revenue | $276 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $90 | -$4,605 | $0 |
| % Margin | 32.4% | – | – |
| EBITDA | -$7,496 | -$14,845 | $0 |
| % Margin | -2,711.4% | – | – |
| Net Income | -$22,444 | -$30,381 | -$41 |
| % Margin | -8,117.8% | – | – |
| EPS Diluted | -5.25 | -8.47 | -0.018 |
| % Growth | 38% | -46,438.5% | – |
| Operating Cash Flow | -$7,875 | -$10,422 | -$75 |
| Capital Expenditures | -$103 | -$33 | $0 |
| Free Cash Flow | -$7,978 | -$10,455 | -$75 |